Long-Term Safety and Efficacy of Eltrombopag for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia: Results of the ASPIRE Extension Study
Acta Haematologica · 2023 · 146 (5) · 373-378
DOI: 10.1159/000531146 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Haematologica, online erschienen am 19.05.2023. Verfasst von Moshe Mittelman und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Leukopenia, Myelodysplastic Syndromes, Thrombocytopenia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
ASPIRE, a three-part, international, phase 2 trial (ClinicalTrials.gov identifier: NCT01440374), investigated eltrombopag efficacy and safety in patients with advanced myelodysplastic syndrome or acute myeloid leukemia and grade 4 thrombocytopenia (<25 × 109 platelets/L). Approximately 30–65% of patients in this open-label extension phase experienced clinically relevant thrombocytopenic events; no conclusions could be made regarding long-term efficacy (non-randomized design, no placebo control), and survival rates may simply reflect advanced disease. Long-term safety was consistent with the double-blind phase and contrasted with earlier SUPPORT study findings in higher-risk patients, suggesting that eltrombopag may have a role in treating thrombocytopenia in patients with low-/intermediate-risk myelodysplastic syndrome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Department of Hematology, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel.
- Medical Clinic and Polyclinic I, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany.
- Department of Hematology and Cancer Prevention, Medical University of Silesia, Katowice, Poland.
- Novartis Pharma AG, Basel, Switzerland.
- Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
- Department of Hematology, AZ Sint-Jan Brugge-Oostende AV, Bruges, Belgium.
Zitieren
APA
Mittelman, M., Platzbecker, U., Grosicki, S., Lawniczek, T., Zhu, Z., & Selleslag, D. (2023). Long-Term Safety and Efficacy of Eltrombopag for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia: Results of the ASPIRE Extension Study. Acta Haematologica, 146(5), 373-378. https://doi.org/10.1159/000531146
Vancouver
Mittelman M, Platzbecker U, Grosicki S, Lawniczek T, Zhu Z, Selleslag D. Long-Term Safety and Efficacy of Eltrombopag for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia: Results of the ASPIRE Extension Study. Acta Haematologica. 2023;146(5):373-378. doi:10.1159/000531146
BibTeX
@article{Mittelman2023,
author = {Mittelman, Moshe and Platzbecker, Uwe and Grosicki, Sebastian and Lawniczek, Tomasz and Zhu, Zewen and Selleslag, Dominik},
title = {Long-Term Safety and Efficacy of Eltrombopag for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia: Results of the ASPIRE Extension Study},
journal = {Acta Haematologica},
year = {2023},
volume = {146},
number = {5},
pages = {373--378},
doi = {10.1159/000531146}
}
EUVIMED